Spotlight on Ustekinumab in Moderate To Severe Plaque Psoriasis

Ustekinumab (Stelara®) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is ind...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2012-04, Vol.13 (2), p.135-137
Main Author: Croxtall, Jamie D.
Format: Article
Language:English
Subjects:
Adis Spotlight
Adult
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - physiopathology
Biological and medical sciences
Dermatologic Agents - adverse effects
Dermatologic Agents - pharmacology
Dermatologic Agents - therapeutic use
Dermatology
Humans
Interleukin-12 - immunology
Interleukin-23 - immunology
Medical sciences
Medicine
Medicine & Public Health
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis - drug therapy
Psoriasis - physiopathology
Psoriasis. Parapsoriasis. Lichen
Quality of Life
Randomized Controlled Trials as Topic
Severity of Illness Index
Ustekinumab
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ustekinumab (Stelara®) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is indicated for those who failed to respond to, have a contraindication to, or are intolerant of other systemic therapies or phototherapy. In well designed, randomized clinical trials, regimens of subcutaneous ustekinumab 45 or 90 mg provided a rapid and durable improvement in Psoriasis Area and Severity Index scores for patients with moderate to severe plaque psoriasis. Treatment with ustekinumab 45 or 90 mg also improved healthrelated quality-of-life scores from baseline. More limited data indicate that ustekinumab also improves the symptoms of arthritis in patients with plaque psoriasis and psoriatic arthritis. Subcutaneous ustekinumab was generally well tolerated in clinical trials; most adverse events were mild in intensity and did not require dosage adjustment. A pooled analysis of clinical trial data indicated no specific patterns of infection for recipients of ustekinumab and that infection rates remained stable following cumulative exposure to the agent. Thus, subcutaneous ustekinumab provides an effective and well tolerated alternative for the symptomatic treatment of patients with moderate to severe plaque psoriasis.
ISSN:1175-0561
1179-1888
DOI:10.2165/11208650-000000000-00000